Research Topics
| Julie KreyenbuhlSummaryAffiliation: University of Maryland Country: USA Publications
| Collaborators
|
Detail Information
Publications
Does adherence to medications for type 2 diabetes differ between individuals with vs without schizophrenia?Julie Kreyenbuhl
Department of Psychiatry, Universityof Maryland School of Medicine, Baltimore, MD 21201
Schizophr Bull 36:428-35. 2010..Future studies should investigate whether factors such as comanagement of a chronic psychiatric illness or regular contact with mental health providers bestow benefits for diabetes self-management in persons with schizophrenia...
Consumer satisfaction with inpatient psychiatric treatment among persons with severe mental illnessAnn Hackman
Department of Psychiatry, University of Maryland, 630 W Fayette Street, 4th Floor, Baltimore, MD 21201, USA
Community Ment Health J 43:551-64. 2007..This may reflect value consumers place on staff time, attention and communication. Teaching may enhance self-efficacy and hope thereby facilitating recovery...
Is implementation of the 5 A's of smoking cessation at community mental health centers effective for reduction of smoking by patients with serious mental illness?Lisa B Dixon
University of Maryland School of Medicine, Department of Psychiatry, Division of Services Research, 737 W Lombard St Room 520, Baltimore, MD 21201, USA
Am J Addict 18:386-92. 2009..Six months of the 5 A's produced no effect. Modest cessation and reduction benefits were noted after 12 months. Implementing the 5 A's at community mental health centers may have modest benefit after twelve months...- Correlates of severity of smoking among persons with severe mental illnessLisa Dixon
Department of Psychiatry, University of Maryland School of Medicine, VA Capitol Health Care Network Mental Illness Research Education and Clinical Center, Baltimore, Maryland 21201, USA
Am J Addict 16:101-10. 2007..The linkage of heavy smoking with poorer quality of life and co-occurring medical disorders suggests the importance of smoking reduction and cessation strategies to reduce smoking and decrease patients' total pack years of smoking... - A comparison of adherence to hypoglycemic medications between Type 2 diabetes patients with and without serious mental illnessJulie Kreyenbuhl
Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Psychiatry Res 188:109-14. 2011..The experience of managing a chronic mental illness may confer advantages to individuals with serious mental illnesses in the self-care of co-occurring medical conditions like Type 2 diabetes... - An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patientsCarol E Koro
School of Pharmacy, University of Maryland, 506 W Fayette St, Suite 201, Baltimore, MD 21201, USA
Arch Gen Psychiatry 59:1021-6. 2002..Previous studies have suggested an association between olanzapine treatment and hyperlipidemia. We evaluated this association using a large health care database... - Predictors of mortality in patients with serious mental illness and co-occurring type 2 diabetesClayton Brown
Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, 660 West Redwood St, Baltimore, MD 21201, USA
Psychiatry Res 177:250-4. 2010..Providers need to be especially vigilant regarding mortality risk when patients require hospitalization for diabetes and as their patients age. Smoking cessation should also be aggressively promoted... - Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophreniaJulie Kreyenbuhl
VA Capitol Healthcare Network VISN 5 Mental Illness Research, Education, and Clinical Center MIRECC, 10 N Greene St BT MIRECC, Baltimore, MD 21201, USA
Schizophr Res 131:127-32. 2011..We investigated discontinuation of selected first- and second-generation antipsychotics among individuals with schizophrenia receiving usual care in a VA healthcare network in the U.S. mid-Atlantic region... - Antidepressant prescribing patterns among VA patients with schizophreniaSeth Himelhoch
Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21212, United States
Schizophr Res 136:32-5. 2012..Recent reviews have questioned the efficacy of adjuvant use of antidepressants for the treatment of depression or the treatment of primary negative symptoms among individuals with schizophrenia... - The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statementsRobert W Buchanan
Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, PO Box 21247, Baltimore, MD 21228, USA
Schizophr Bull 36:71-93. 2010.... - Care and management of cardiovascular risk factors among individuals with schizophrenia and type 2 diabetes who smokeSeth Himelhoch
University of Maryland School of Medicine, Baltimore, MD 21201, USA
Gen Hosp Psychiatry 31:30-2. 2009..We sought to determine whether individuals with schizophrenia and type 2 diabetes who smoke were being monitored and treated for modifiable risk factors associated with cardiovascular disease... - Predictors of HIV and hepatitis testing and related service utilization among individuals with serious mental illnessRichard W Goldberg
University of Maryland Baltimore School of Medicine, Division of Services Research, and the VA Capitol Health Care Network Mental Illness Research, Education and Clinical Center, Baltimore, MD 21201, USA
Psychosomatics 46:573-7. 2005..Only 15% of the sample was immunized against hepatitis B. Medical hospitalization was the only factor related to immunization. These results indicate an urgent need to improve access to HIV and hepatitis testing and related treatment... - Long-term combination antipsychotic treatment in VA patients with schizophreniaJulie Kreyenbuhl
Division of Services Research, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Schizophr Res 84:90-9. 2006..The most commonly used antipsychotic combinations have little support for safety or efficacy. Further research is needed to understand the impact of these treatments on symptoms, side effects, and costs... - Extent and management of cardiovascular risk factors in patients with type 2 diabetes and serious mental illnessJulie Kreyenbuhl
Division of Services Research, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
J Nerv Ment Dis 194:404-10. 2006..Patients with both diabetes and SMI are treated less aggressively for high cardiovascular risk than diabetes patients without mental disorders... - Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetesJulie Kreyenbuhl
Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Schizophr Res 101:256-65. 2008..Inadequate pharmacologic care for CVD may partially explain poor health outcomes in individuals with both conditions. We sought to identify patients in this group at greatest risk for suboptimal pharmacologic management... - The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003Anthony F Lehman
Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Schizophr Bull 30:193-217. 2004.... - Living well: an intervention to improve self-management of medical illness for individuals with serious mental illnessRichard W Goldberg
Department of Veterans Affairs Capitol Health Care Network VISN 5, Mental Illness Research, Education and Clinical Center, 10 N Greene St, Baltimore, MD 21201, USA
Psychiatr Serv 64:51-7. 2013..This study examined the effectiveness of a modified version of the Chronic Disease Self-Management Program called Living Well for individuals with serious mental illness... - Use of a critical time intervention to promote continuity of care after psychiatric inpatient hospitalizationLisa Dixon
Department of Psychiatry, University of Maryland School of Medicine, 737 West Baltimore St, Baltimore, MD 21201, USA
Psychiatr Serv 60:451-8. 2009.... - Comorbidity of medical illnesses among adults with serious mental illness who are receiving community psychiatric servicesJoseph Sokal
Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA
J Nerv Ment Dis 192:421-7. 2004..The odds of diabetes, lung diseases, and liver problems are particularly elevated. These findings underscore the need for intensified preventive health interventions and medical services for this population... - Prevalence of chronic obstructive pulmonary disease among those with serious mental illnessSeth Himelhoch
Department of Psychiatry, Division of Mental Health Services Research, University of Maryland School of Medicine, 685 West Baltimore St, MSTF Building, Suite 300, Baltimore, MD 21201 1549, USA
Am J Psychiatry 161:2317-9. 2004..The goal was to determine the prevalence of COPD among those with serious mental illness... - Disengagement from mental health treatment among individuals with schizophrenia and strategies for facilitating connections to care: a review of the literatureJulie Kreyenbuhl
Division of Services Research, Department of Psychiatry, University of Maryland School of Medicine, 5th Floor, 737 West Lombard Street, Baltimore, MD 21201, USA
Schizophr Bull 35:696-703. 2009.... - Evidence-based treatment for schizophreniaAnthony F Lehman
Department of Psychiatry University of Maryland School of Medicine, 701 West Pratt Street, Suite 388, Baltimore, MD 21201, USA
Psychiatr Clin North Am 26:939-54. 2003..Knowledge regarding how best to combine treatments to optimize outcomes is scarce... - Adding or switching antipsychotic medications in treatment-refractory schizophreniaJulie Kreyenbuhl
Department of Psychiatry, Division of Services Research, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Psychiatr Serv 58:983-90. 2007..Psychiatrists' characteristics and perceptions of effectiveness of the medication change on clinical outcomes were also reported... - Specifying cigarette smoking and quitting among people with serious mental illnessAlicia Lucksted
Center for Mental Health Services Research, Department of Psychiatry, University of Maryland, 685 West Baltimore Street, MSTF Building Suite 300, Baltimore, MD 21201, USA
Am J Addict 13:128-38. 2004.... - The schizophrenia PORT pharmacological treatment recommendations: conformance and implications for symptoms and functional outcomeRobert W Buchanan
Maryland Psychiatric Research Center, Baltimore 21228, USA
Schizophr Bull 28:63-73. 2002..Patients treated with conventional antipsychotic doses below the recommended dose range had significantly better role function. Prospective longitudinal studies are required to delineate the factors that may underlie this relationship... - Racial disparity in the pharmacological management of schizophreniaJulie Kreyenbuhl
Mental Illness Research, Education, and Clinical Center, VAMHCS Baltimore, MD 21201, USA
Schizophr Bull 29:183-93. 2003..A prospective, longitudinal evaluation is warranted to determine whether the observed patterns of prescribing are associated with poorer therapeutic outcomes in minority patients... - Physical wellness and employment status among adults with serious mental illnessRichard W Goldberg
VA Capitol Health Care Network, VISN 5, Mental Illness Research, Education and Clinical Center, Baltimore, MD, USA
Community Ment Health J 44:245-51. 2008..Recommendations to enhance existing models of supported employment programs with physical health and wellness promotion components are offered... - The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statementsLisa B Dixon
VA Capitol Health Care Network Mental Illness Research Education and Clinical Center, Baltimore, MD, USA
Schizophr Bull 36:48-70. 2010.... - The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009Julie Kreyenbuhl
VA Capitol Health care Network VISN 5 Mental Illness Research, Education, and Clinical Center, Baltimore, MD, USA
Schizophr Bull 36:94-103. 2010..Another 13 psychopharmacologic and 4 psychosocial treatments had insufficient evidence to support a recommendation, representing significant unmet needs in important treatment domains... - Clozapine underutilization and discontinuation in African Americans due to leucopeniaDeanna L Kelly
The Maryland Psychiatric Research Center, Box 21247, Baltimore, MD 21228, USA
Schizophr Bull 33:1221-4. 2007.... - Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control studyCarol E Koro
Pharmaceutical Health Services Research Department, School of Pharmacy, University of Maryland, Baltimore, MD 21201, USA
BMJ 325:243. 2002..2, 0.9 to 5.2) and those taking conventional antipsychotics (1.6, 0.7 to 3.8). CONCLUSION: Olanzapine is associated with a clinically important and significant increased risk of diabetes... - Relationship of the use of adjunctive pharmacological agents to symptoms and level of function in schizophreniaRobert W Buchanan
Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland, Baltimore, 21228, USA
Am J Psychiatry 159:1035-43. 2002.... - Novel factor-based symptom scores in treatment resistant schizophrenia: implications for clinical trialsRobert P McMahon
Department of Psychiatry, Maryland Psychiatric Research Center, Spring Grove Hospital Grounds, Maple and Locust Avenues, PO Box 21247, Baltimore, MD 21228, USA
Neuropsychopharmacology 26:537-45. 2002..We recommend these four factor scores as clinical trial outcomes in patients with treatment resistant schizophrenia...